Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 438945, 8 pages
http://dx.doi.org/10.1155/2014/438945
Clinical Study

Posttransplant Allosensitization in Low Immunological Risk Kidney and Kidney-Pancreas Graft Recipients

1Nephrology and Kidney Transplantation Department, Centro Hospitalar do Porto, Hospital de Santo António, Largo Prof. Abel Salazar, 4099-001 Porto, Portugal
2Centro do Sangue e Transplantação do Porto, Rua de Bolama No. 133, 4200-139 Porto, Portugal

Received 23 February 2014; Accepted 1 April 2014; Published 15 April 2014

Academic Editor: Rafia Al-Lamki

Copyright © 2014 Jorge Malheiro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Akalin and M. Pascual, “Sensitization after kidney transplantation,” Clinical journal of the American Society of Nephrology, vol. 1, no. 3, pp. 433–440, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. H. M. Gebel and R. A. Bray, “Sensitization and sensitivity: defining the unsensitized patient,” Transplantation, vol. 69, no. 7, pp. 1370–1374, 2000. View at Google Scholar · View at Scopus
  3. S. Martin, P. A. Dyer, N. P. Mallick, R. Gokal, R. Harris, and R. W. Johnson, “Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome,” Transplantation, vol. 44, no. 1, pp. 50–53, 1987. View at Google Scholar · View at Scopus
  4. C. Wiebe, I. W. Gibson, T. D. Blydt-Hansen et al., “Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant,” American Journal of Transplantation, vol. 12, no. 5, pp. 1157–1167, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. M. J. Everly, L. M. Rebellato, C. E. Haisch et al., “Incidence and impact of de novo donor-specific alloantibody in primary renal allografts,” Transplantation, vol. 95, pp. 410–417, 2013. View at Google Scholar
  6. M. Hourmant, A. Cesbron-Gautier, P. I. Terasaki et al., “Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation,” Journal of the American Society of Nephrology, vol. 16, no. 9, pp. 2804–2812, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. R. P. Pelletier, P. K. Hennessy, P. W. Adams, A. M. VanBuskirk, R. M. Ferguson, and C. G. Orosz, “Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation,” American Journal of Transplantation, vol. 2, no. 2, pp. 134–141, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. P. I. Terasaki and M. Ozawa, “Predicting kidney graft failure by HLA antibodies: a prospective trial,” American Journal of Transplantation, vol. 4, no. 3, pp. 438–443, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. B. D. Tait, C. Susal, H. M. Gebel et al., “Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation,” Transplantation, vol. 95, pp. 19–47, 2013. View at Google Scholar
  10. D. Cantarovich, S. de Amicis, A. Akl et al., “Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome,” American Journal of Transplantation, vol. 11, no. 12, pp. 2737–2746, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Ginevri, A. Nocera, P. Comoli et al., “Posttransplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection,” American Journal of Transplantation, vol. 12, pp. 3355–3362, 2012. View at Google Scholar
  12. K. J. Tinckam, I. G. Wood, F. Ji, and E. L. Milford, “ATG induction is associated with an increase in anti-HLA antibodies after kidney transplantation,” Human Immunology, vol. 65, no. 11, pp. 1281–1287, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Masson, N. Devillard, J. Chabod et al., “Misleading de novo detection of serum anti-HLA-A3 antibodies in kidney recipients having received ATG before transplantation,” Human Immunology, vol. 71, no. 2, pp. 170–175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. I. Colovai, E. R. Vasilescu, A. Foca-Rodi et al., “Acute and hyperacute humoral rejection in kidney allograft recipients treated with anti-human thymocyte antibodies,” Human Immunology, vol. 66, no. 5, pp. 501–512, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Lefaucheur, A. Loupy, D. Vernerey et al., “Antibody-mediated vascular rejection of kidney allografts: a population-based study.,” The Lancet, vol. 381, pp. 313–319, 2013. View at Google Scholar
  16. C. Wiebe and P. Nickerson, “Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation,” Current Opinion in Organ Transplantation, vol. 18, pp. 470–477, 2013. View at Google Scholar
  17. T. Shimizu, H. Ishida, H. Shirakawa et al., “Clinicopathological analysis of acute vascular rejection cases after renal transplantation,” Clinical Transplantation, vol. 24, supplement 22, pp. 22–26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Lachmann, P. I. Terasaki, K. Budde et al., “Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts,” Transplantation, vol. 87, no. 10, pp. 1505–1513, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. J. E. Cooper, J. Gralla, L. Cagle, R. Goldberg, L. Chan, and A. C. Wiseman, “Inferior kidney allograft outcomes in patients with de Novo Donor-Specific antibodies are due to acute rejection episodes,” Transplantation, vol. 91, no. 10, pp. 1103–1109, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Piazza, E. Pocci, L. Borrelli et al., “Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques1,” Transplantation, vol. 71, no. 8, pp. 1106–1112, 2001. View at Google Scholar · View at Scopus
  21. L. G. Hidalgo, P. M. Campbell, B. Sis et al., “De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure,” American Journal of Transplantation, vol. 9, no. 11, pp. 2532–2541, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. X. Li, H. Ishida, Y. Yamaguchi, and K. Tanabe, “Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation,” Transplant International, vol. 21, no. 12, pp. 1145–1152, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Cardarelli, M. Pascual, N. Tolkoff-Rubin et al., “Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation,” Transplant International, vol. 18, no. 5, pp. 532–540, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. P.-C. Lee, L. Zhu, P. I. Terasaki, and M. J. Everly, “HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss,” Transplantation, vol. 88, no. 4, pp. 568–574, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. É. F. Campos, H. Tedesco-Silva, P. G. Machado, M. Franco, J. O. Medina-Pestana, and M. Gerbase-DeLima, “Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure,” American Journal of Transplantation, vol. 6, no. 10, pp. 2316–2320, 2006. View at Publisher · View at Google Scholar · View at Scopus